T細胞リンパ腫市場- 世界の産業規模、シェア、動向、機会および予測、タイプ別、治療法別、地域別、競争別セグメント、2020-2030F

T細胞リンパ腫の世界市場規模は2024年に22億6,000万米ドルとなり、予測期間中は堅調な成長を遂げ、2030年までCAGR 8.62％で拡大すると予測されています。

T細胞リンパ腫は非ホジキンリンパ腫（NHL）のサブセットであり、リンパ節、リンパ管、脾臓、胸腺からなる免疫系の重要な構成要素であるリンパ系に発生する悪性腫瘍です。具体的には、T細胞リンパ腫は異常なTリンパ球（T細胞）から発生します。T細胞は白血球の一種で、感染した細胞や異常な細胞を識別し排除する上で重要な役割を果たしています。

T細胞リンパ腫の臨床症状は、サブタイプや病期によって異なります。一般的な症状としては、リンパ節腫大、持続する発熱、寝汗、意図しない体重減少、疲労、そして皮膚T細胞リンパ腫（CTCL）の場合は皮膚の異常が挙げられます。診断には通常、病歴の検討、身体診察、臨床検査、画像検査（CTやPETスキャンなど）、組織生検を含む集学的アプローチが必要です。多くの場合、疾患のサブタイプを決定し、治療戦略を決定するために分子検査や遺伝子検査が行われます。

主な市場促進要因

T細胞リンパ腫の発生率と有病率の上昇

主な市場課題

治療抵抗性

主要市場動向

新興治療薬への患者アクセスの強化

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 T細胞リンパ腫市場展望

• 市場規模・予測
  • 金額別
• 市場シェア・予測
  • 種類別（末梢性（皮膚T細胞リンパ腫、未分化大細胞リンパ腫、血管免疫芽球性T細胞リンパ腫、その他）、リンパ芽球性）
  • 治療法別（放射線療法、化学療法、免疫療法、幹細胞移植、その他）
  • 地域別
  • 企業別（2024）
• 市場マップ

第6章 北米のT細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 北米：国別分析
  • 米国
  • カナダ
  • メキシコ

第7章 欧州のT細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 欧州：国別分析
  • ドイツ
  • 英国
  • イタリア
  • フランス
  • スペイン

第8章 アジア太平洋地域のT細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• アジア太平洋地域：国別分析
  • 中国
  • インド
  • 日本
  • 韓国
  • オーストラリア

第9章 南米のT細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 南米：国別分析
  • ブラジル
  • アルゼンチン
  • コロンビア

第10章 中東・アフリカのT細胞リンパ腫市場展望

• 市場規模・予測
• 市場シェア・予測
• 中東・アフリカ：国別分析
  • 南アフリカ
  • サウジアラビア
  • アラブ首長国連邦

第11章 市場力学

• 促進要因
• 課題

第12章 市場動向と発展

• 最近の動向
• 製品上市
• 合併と買収

第13章 世界のT細胞リンパ腫市場：SWOT分析

第14章 競合情勢

• Acrotech Biopharma Inc.
• Affimed GmbH
• Bristol-Myers Squibb Company
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Citius Pharmaceuticals, Inc
• DAIICHI SANKYO COMPANY, LIMITED
• Eisai Co., Ltd.
• Genor Biopharma Co. Ltd
• Innate Pharma SA
• Digene Pharmaceuticals Co., Ltd.

第15章 戦略的提言

第16章 調査会社について・免責事項

The global T-cell lymphoma market was valued at USD 2.26 billion in 2024 and is projected to experience robust growth over the forecast period, expanding at a CAGR of 8.62% through 2030. T-cell lymphoma is a subset of non-Hodgkin lymphoma (NHL), a malignancy originating in the lymphatic system-a vital component of the immune system comprising lymph nodes, lymphatic vessels, the spleen, and thymus. Specifically, T-cell lymphomas develop from abnormal T lymphocytes (T cells), a type of white blood cell that plays a critical role in identifying and eliminating infected or abnormal cells.

The clinical presentation of T-cell lymphoma varies based on its subtype and disease stage. Common symptoms include enlarged lymph nodes, persistent fever, night sweats, unintended weight loss, fatigue, and, in the case of cutaneous T-cell lymphoma (CTCL), skin abnormalities. Diagnosis typically involves a multidisciplinary approach, including a review of medical history, physical examination, laboratory testing, imaging studies (such as CT or PET scans), and tissue biopsy. In many cases, molecular and genetic testing is employed to determine disease subtype and inform therapeutic strategies.

Key Market Drivers

Rising Incidence and Prevalence of T-Cell Lymphoma

A major driver of market expansion is the increasing global incidence and prevalence of T-cell lymphoma. Though T-cell lymphomas account for only 5-10% of NHL cases in Western markets, they represent a clinically significant segment due to their diverse biological and clinical profiles. Among the most commonly diagnosed subtypes are Peripheral T-cell Lymphoma Not Otherwise Specified (PTCL-NOS) and Angioimmunoblastic T-cell Lymphoma (AITL), which continue to attract considerable attention for therapeutic development and commercial investment.

Despite being considered rare, recent epidemiological data suggests a gradual global uptick in T-cell lymphoma diagnoses. This growing disease burden is creating both an urgent medical need and a significant commercial opportunity. As diagnoses rise across various subtypes-including PTCL, CTCL, and AITL-there is an increasing demand for advanced diagnostic technologies, targeted therapies, and long-term disease management solutions. In response, pharmaceutical and biotechnology companies, along with healthcare providers, are investing more heavily in research and development to deliver effective, patient-centric treatment options.

Key Market Challenges

Treatment Resistance

One of the most pressing challenges in the T-cell lymphoma market is treatment resistance, wherein cancer cells exhibit reduced sensitivity or complete non-responsiveness to therapy. This phenomenon complicates disease management and hinders long-term remission. The biological and clinical heterogeneity of T-cell lymphomas makes it particularly difficult to establish uniform treatment protocols, with certain subtypes demonstrating higher resistance levels.

Although therapeutic advancements have been made, the treatment landscape for T-cell lymphoma remains relatively limited compared to other cancers. This scarcity of options becomes particularly problematic when patients develop resistance to frontline therapies. Resistance may be intrinsic-present at diagnosis-or acquired during the treatment course. Understanding the mechanisms behind this resistance is essential to developing personalized and adaptive therapeutic strategies.

Key Market Trends

Enhanced Patient Access to Emerging Therapies

Improving patient access to innovative therapies is an evolving trend in the T-cell lymphoma market. Pharmaceutical companies, in collaboration with regulatory bodies, are increasingly launching early access and compassionate use programs, enabling eligible patients to receive promising treatments prior to full market approval. These initiatives are especially critical for individuals with limited existing options.

Efforts are also being made to secure multi-regional regulatory approvals and pursue label expansions to cover broader patient populations and additional indications. Stakeholders-including patient advocacy organizations, healthcare providers, and policymakers-are working to dismantle barriers to access by addressing cost-related challenges, insurance limitations, and reimbursement policies.

Innovative pricing models and reimbursement frameworks, developed through collaboration among pharmaceutical companies, healthcare systems, and payers, are facilitating greater access while maintaining financial sustainability. Additionally, initiatives to promote clinical trial participation and educate patients on emerging therapies empower individuals to make informed decisions and explore advanced treatment options.

Key Market Players

• Acrotech Biopharma Inc.
• Affimed GmbH
• Bristol-Myers Squibb Company
• Shenzhen Chipscreen Biosciences Co., Ltd.
• Citius Pharmaceuticals, Inc
• DAIICHI SANKYO COMPANY, LIMITED
• Eisai Co., Ltd.
• Genor Biopharma Co. Ltd
• Innate Pharma SA
• Digene Pharmaceuticals Co., Ltd.

Report Scope:

In this report, the Global T-Cell Lymphoma Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

T-Cell Lymphoma Market, By Type:

• Peripheral {Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Other}
• Lymphoblastic

T-Cell Lymphoma Market, By Therapy:

• Radiotherapy
• Chemotherapy
• Immunotherapy
• Stem Cell Transplantation
• Other

T-Cell Lymphoma Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global T-Cell Lymphoma Market.

Available Customizations:

Global T-Cell Lymphoma Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. T-Cell Lymphoma Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Type (Peripheral {Cutaneous T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angio-immuno-blastic T-cell Lymphoma, Other}, Lymphoblastic)
  • 5.2.2. By Therapy (Radiotherapy, Chemotherapy, Immunotherapy, Stem Cell Transplantation, Other)
  • 5.2.3. By Region
  • 5.2.4. By Company (2024)
• 5.3. Market Map

6. North America T-Cell Lymphoma Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Type
  • 6.2.2. By Therapy
  • 6.2.3. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States T-Cell Lymphoma Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Type
      • 6.3.1.2.2. By Therapy
  • 6.3.2. Canada T-Cell Lymphoma Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Type
      • 6.3.2.2.2. By Therapy
  • 6.3.3. Mexico T-Cell Lymphoma Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Type
      • 6.3.3.2.2. By Therapy

7. Europe T-Cell Lymphoma Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Type
  • 7.2.2. By Therapy
  • 7.2.3. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany T-Cell Lymphoma Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Type
      • 7.3.1.2.2. By Therapy
  • 7.3.2. United Kingdom T-Cell Lymphoma Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Type
      • 7.3.2.2.2. By Therapy
  • 7.3.3. Italy T-Cell Lymphoma Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Type
      • 7.3.3.2.2. By Therapy
  • 7.3.4. France T-Cell Lymphoma Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Type
      • 7.3.4.2.2. By Therapy
  • 7.3.5. Spain T-Cell Lymphoma Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Type
      • 7.3.5.2.2. By Therapy

8. Asia-Pacific T-Cell Lymphoma Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Type
  • 8.2.2. By Therapy
  • 8.2.3. By Country
• 8.3. Asia-Pacific: Country Analysis
  • 8.3.1. China T-Cell Lymphoma Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Type
      • 8.3.1.2.2. By Therapy
  • 8.3.2. India T-Cell Lymphoma Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Type
      • 8.3.2.2.2. By Therapy
  • 8.3.3. Japan T-Cell Lymphoma Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Type
      • 8.3.3.2.2. By Therapy
  • 8.3.4. South Korea T-Cell Lymphoma Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Type
      • 8.3.4.2.2. By Therapy
  • 8.3.5. Australia T-Cell Lymphoma Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Type
      • 8.3.5.2.2. By Therapy

9. South America T-Cell Lymphoma Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Type
  • 9.2.2. By Therapy
  • 9.2.3. By Country
• 9.3. South America: Country Analysis
  • 9.3.1. Brazil T-Cell Lymphoma Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Type
      • 9.3.1.2.2. By Therapy
  • 9.3.2. Argentina T-Cell Lymphoma Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Type
      • 9.3.2.2.2. By Therapy
  • 9.3.3. Colombia T-Cell Lymphoma Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Type
      • 9.3.3.2.2. By Therapy

10. Middle East and Africa T-Cell Lymphoma Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Type
  • 10.2.2. By Therapy
  • 10.2.3. By Country
• 10.3. MEA: Country Analysis
  • 10.3.1. South Africa T-Cell Lymphoma Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Type
      • 10.3.1.2.2. By Therapy
  • 10.3.2. Saudi Arabia T-Cell Lymphoma Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Type
      • 10.3.2.2.2. By Therapy
  • 10.3.3. UAE T-Cell Lymphoma Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Type
      • 10.3.3.2.2. By Therapy

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Recent Developments
• 12.2. Product Launches
• 12.3. Mergers & Acquisitions

13. Global T-Cell Lymphoma Market: SWOT Analysis

14. Competitive Landscape

• 14.1. Acrotech Biopharma Inc.
  • 14.1.1. Business Overview
  • 14.1.2. Product & Service Offerings
  • 14.1.3. Recent Developments
  • 14.1.4. Financials (If Listed)
  • 14.1.5. Key Personnel
  • 14.1.6. SWOT Analysis
• 14.2. Affimed GmbH
• 14.3. Bristol-Myers Squibb Company
• 14.4. Shenzhen Chipscreen Biosciences Co., Ltd.
• 14.5. Citius Pharmaceuticals, Inc
• 14.6. DAIICHI SANKYO COMPANY, LIMITED
• 14.7. Eisai Co., Ltd.
• 14.8. Genor Biopharma Co. Ltd
• 14.9. Innate Pharma SA
• 14.10.Digene Pharmaceuticals Co., Ltd.

15. Strategic Recommendations

16. About Us & Disclaimer